IKT
Inhibikase Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Inhibikase Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
0.01%
IKT weight · IWM
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Inhibikase Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Inhibikase Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Inhibikase Therapeutics, Inc.
1.49
−0.05 · −3.25%
post 1.49 0.00%
| Manager | Value | % base | |
|---|---|---|---|
| Sands Capital Ventures | $26.4M | 10.86% | 0.00% |
| Soleus | $22.1M | 9.07% | 0.00% |
| Trails Edge Capital Partners | $18.4M | 7.55% | +12.34% |
| Fairmount Funds | $17.5M | 7.19% | 0.00% |
| BlackRockindex-like | $15.8M | 6.48% | +23.24% |
| Manager | Value | % base | |
|---|---|---|---|
| Sands Capital Ventures | $26.4M | 10.86% | 0.00% |
| Soleus | $22.1M | 9.07% | 0.00% |
| Trails Edge Capital Partners | $18.4M | 7.55% | +12.34% |
| Fairmount Funds | $17.5M | 7.19% | 0.00% |
| BlackRockindex-like | $15.8M | 6.48% | +23.24% |
+4.96%
shares held · 10 largest managers
Bull2
Bear1
Expected move
No implied move.